Yes, an Australian plastic surgeon can run Google Ads compliantly – but only for a narrower set of things than most practices assume, and the cost is not primarily the click price. The cost is the compliance overhead, the loss of the highest-intent keywords, and the discipline required to keep a landing page factual when the entire logic of paid search pushes towards persuasion. Whether that trade is worth making depends on what the practice is actually trying to buy.
Three rule sets apply simultaneously, and they are not the same rules. The first is the Health Practitioner Regulation National Law and the AHPRA advertising guidelines, including the additional guidelines for registered medical practitioners who advertise cosmetic surgery, which are more stringent than the general requirements. The second is the therapeutic goods advertising framework administered by the TGA, which governs any reference to the products used. The third is Google’s own healthcare and medicines policy, which is a private platform rule rather than law but which determines whether the ad runs at all.
The practical significance is that compliance with one is not compliance with the others. An ad can satisfy Google’s automated review and still breach the National Law. It can satisfy AHPRA and still be rejected by Google. And a practice that also offers non-surgical work now sits under a further layer again: AHPRA’s guidelines for practitioners who advertise higher risk non-surgical cosmetic procedures commenced on 2 September 2025 and apply across all regulated professions.
Certain content is unavailable regardless of how the campaign is structured. The list below is a starting point for a compliance conversation rather than a substitute for one:
Where images are used in advertising higher risk non-surgical procedures, the 2025 guidelines require that images be real and unedited in any way that misleads, and that the advertising carry a warning that results may vary between patients.
Cosmetic injectables that contain prescription-only medicines cannot be advertised to the public because prescription-only medicines cannot be advertised to consumers in Australia. The TGA’s position, set out in its guidance on advertising health services and cosmetic injections, is that the prohibition captures direct and indirect references alike – brand names, active ingredient names, coded slang, before-and-after images of injectable results, and price lists for those treatments.
This is where a good deal of practice advertising quietly goes wrong, because the restriction is on the goods rather than the service. A practice may advertise that it provides consultations and treatments in a general sense; it may not advertise the prescription medicine that makes the treatment work. Google reinforces the same boundary from its side: its Australia-specific restrictions state that ads targeting Australia can’t use prescription drug terms in the ad or its destination – meaning the landing page is caught as well as the ad text.
What remains is the practice itself: the surgeon’s name and specialist registration, qualifications and fellowship, consulting locations, the availability and cost of an initial consultation, hospital affiliations, subspecialty focus, and how to obtain and use a referral. This is a genuinely usable set of messages, but it is a different proposition from the one most paid search campaigns are built to sell.
The commercial consequence is worth stating plainly. The highest-intent keywords in this category are procedure keywords, and procedure keywords lead almost inevitably towards claims and comparisons that the guidelines prohibit. A campaign restricted to compliant messaging must therefore compete for those searches with an ad that says less than its non-compliant competitors – and sometimes less than practices that are simply not being policed yet. That asymmetry is real, and any agency that does not raise it before taking a budget is not being straight with you.
The cost sits in four places, only one of which appears on the invoice from Google. There is the media spend itself, which in this category is not cheap. There is the build: compliant ad copy, keyword exclusions and a landing page written to the same standard as the ad, since the destination page forms part of the advertisement. There is the ongoing review burden, because search terms drift, automated matching introduces queries nobody chose, and disapprovals require rework. And there is the surgeon’s own time in sign-off, which is the scarcest input in any specialist practice.
Against that, the enquiries a compliant campaign produces are typically well-qualified precisely because the copy is factual – people who respond to a consultation-and-credentials message are further along than people who are ‘just researching’. The honest framing is that paid search here buys immediacy at a premium, and that many practices would get more durable value from putting the same money into assets they own. Where a practice is already at or near capacity, that calculation almost always favours the organic route, as the pattern in our search optimisation case study illustrates.
Paid search is the right decision in specific circumstances: opening a new consulting location, launching a new subspecialty service, filling a genuine gap in the book, defending against competitors bidding on the surgeon’s own name, or where a practice needs enquiries within weeks rather than months. In each of those cases the point is speed, and paid search is the only channel that delivers it.
It is the wrong decision when it is being used to substitute for a practice’s own information assets. A practice whose website does not clearly state its locations, scope and referral pathway will pay for clicks that go nowhere, and will keep paying for them indefinitely. It is also increasingly worth weighing against the shift in how patients search at all: a growing share of the research phase now happens inside AI assistants that do not serve ads, which is the case for building the kind of factual, citable material discussed in our overview of AI and generative search optimisation.
Yes. A plastic surgeon can advertise a regulated health service through Google Ads provided the advertising complies with the National Law, the AHPRA advertising guidelines and the additional cosmetic surgery requirements, and provided the account meets Google’s own healthcare advertising policies. What cannot be advertised is a prescription-only medicine, and what cannot appear includes testimonials about clinical care, outcome claims and modified before-and-after imagery.
Yes. The destination page is treated as part of the advertisement by both AHPRA and Google, so a compliant ad pointing at a page carrying testimonials, modified before-and-after galleries or prescription drug terms does not solve the problem. In practice the landing page is the more common point of failure, because it is often an existing page written before the current guidelines.
Two separate consequences can follow. Google may disapprove the ad or, for repeated issues, suspend the account, which is a commercial problem rather than a regulatory one. Separately, advertising that breaches the National Law can result in regulatory action by AHPRA, and any resulting notification is a considerably more serious matter for a specialist than a rejected ad. Practices should also expect that competitors and members of the public do report advertising.
They answer different questions. Paid search buys immediate visibility at a recurring cost and stops the moment the budget stops; organic search and AI visibility take longer to build but continue working without ongoing spend. A practice needing enquiries this month should use paid search; a practice building a durable referral and enquiry pipeline should prioritise its own website and factual content, and treat paid search as a supplement.
If you would like a plain read on whether paid search is worth it for your practice – including the case for not doing it – we are happy to talk it through. Book a discovery call with us today.